LU93096I2 - Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha) - Google Patents

Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha) Download PDF

Info

Publication number
LU93096I2
LU93096I2 LU93096C LU93096C LU93096I2 LU 93096 I2 LU93096 I2 LU 93096I2 LU 93096 C LU93096 C LU 93096C LU 93096 C LU93096 C LU 93096C LU 93096 I2 LU93096 I2 LU 93096I2
Authority
LU
Luxembourg
Prior art keywords
repatha
evolocumab
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU93096C
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39951467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93096(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of LU93096I2 publication Critical patent/LU93096I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
LU93096C 2007-08-23 2016-06-01 Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha) LU93096I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95766807P 2007-08-23 2007-08-23
US896507P 2007-12-21 2007-12-21
US1063008P 2008-01-09 2008-01-09
US8613308P 2008-08-04 2008-08-04
PCT/US2008/074097 WO2009026558A1 (fr) 2007-08-23 2008-08-22 Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (pcsk9)

Publications (1)

Publication Number Publication Date
LU93096I2 true LU93096I2 (fr) 2016-08-01

Family

ID=39951467

Family Applications (2)

Application Number Title Priority Date Filing Date
LU93096C LU93096I2 (fr) 2007-08-23 2016-06-01 Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU93180C LU93180I2 (fr) 2007-08-23 2016-08-18 Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU93180C LU93180I2 (fr) 2007-08-23 2016-08-18 Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)

Country Status (42)

Country Link
US (27) US8030457B2 (fr)
EP (3) EP3666797B1 (fr)
JP (7) JP5441905B2 (fr)
KR (10) KR20260006647A (fr)
CN (8) CN104311667A (fr)
AR (1) AR068011A1 (fr)
AU (1) AU2008288791B2 (fr)
BR (2) BRPI0816117B8 (fr)
CA (1) CA2696252C (fr)
CL (1) CL2008002495A1 (fr)
CO (1) CO6230997A2 (fr)
CR (1) CR11328A (fr)
CY (3) CY1117940T1 (fr)
DE (2) DE19207796T9 (fr)
DK (2) DK3666797T5 (fr)
EA (1) EA032106B1 (fr)
ES (3) ES2946083T3 (fr)
FI (2) FI3666797T3 (fr)
FR (1) FR16C0025I2 (fr)
HR (2) HRP20160494T4 (fr)
HU (4) HUE028162T2 (fr)
IL (5) IL304868A (fr)
JO (1) JOP20080381B1 (fr)
LT (3) LT3666797T (fr)
LU (2) LU93096I2 (fr)
MA (1) MA31978B1 (fr)
MX (3) MX2010001921A (fr)
MY (3) MY199053A (fr)
NL (1) NL300818I2 (fr)
NO (3) NO2016010I1 (fr)
NZ (1) NZ584101A (fr)
PE (8) PE20221507A1 (fr)
PH (2) PH12013502285B1 (fr)
PL (2) PL3666797T3 (fr)
PT (1) PT3666797T (fr)
RS (2) RS64295B1 (fr)
SG (2) SG10201710183TA (fr)
SI (2) SI3666797T1 (fr)
TN (1) TN2010000063A1 (fr)
TW (7) TWI675846B (fr)
UA (1) UA127402C2 (fr)
WO (1) WO2009026558A1 (fr)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
EP2194128B1 (fr) 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Compositions et procédés d'inhibition d'expression du gène PCSK9
EP2083861A4 (fr) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonistes de pcsk9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615114B1 (fr) 2007-08-23 2022-04-06 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2009134487A2 (fr) * 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Procédés optimisés d'administration d'arnds ciblant le gène pcsk9
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
ES2808660T3 (es) 2008-08-04 2021-03-01 Amgen Inc Proteínas de unión a antígeno para proproteína convertasa subtilisina kexina tipo 9 (PCSK9)
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
KR20120050429A (ko) * 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
WO2011028938A1 (fr) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
PE20121544A1 (es) * 2009-09-03 2012-12-02 Pfizer Vaccines Llc Vacuna de pcsk9
WO2011037791A1 (fr) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
EP2494355A4 (fr) * 2009-10-30 2013-05-01 Merck Sharp & Dohme Dosage immunologique de pcsk9
EP2493507A4 (fr) 2009-10-30 2013-11-20 Merck Sharp & Dohme Antagonistes et variants ax213 et ax132 pcsk9
WO2011053759A1 (fr) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
WO2011087934A2 (fr) 2010-01-12 2011-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccins dérivés de kexine destinés à prévenir ou traiter des infections fongiques
US9181538B1 (en) 2010-01-12 2015-11-10 Karen A. Norris Kexin-based vaccines to prevent or treat fungal infections
EP2545079A2 (fr) * 2010-03-11 2013-01-16 Rinat Neuroscience Corporation Anticorps présentant une liaison à l'antigène dépendante du ph
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
BR112013018740A2 (pt) * 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
EP2650016A1 (fr) * 2011-01-28 2013-10-16 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement basés sur des régimes de dosage particuliers (11565)
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
CN103562227B (zh) * 2011-02-11 2016-12-21 诺瓦提斯公司 Pcsk9拮抗剂
EP3604330A1 (fr) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Anticorps fc spécifique au fcgammariib
EP3421592B1 (fr) 2011-04-28 2023-09-13 The Board of Trustees of the Leland Stanford Junior University Identification de polynucléotides associés à un échantillon
JP6081714B2 (ja) * 2011-04-28 2017-02-15 株式会社ビー・エム・エル 高コレステロール血症と動脈硬化の検出方法
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
WO2012170607A2 (fr) * 2011-06-10 2012-12-13 Novartis Ag Utilisation d'antagonistes de pcsk9
WO2012168491A1 (fr) * 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
US9890218B2 (en) 2011-06-30 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CA2840482C (fr) * 2011-07-14 2018-10-16 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP3045188B1 (fr) 2011-10-14 2020-12-23 Amgen Inc. Injecteur et procédé d'assemblage
US20140228539A1 (en) * 2011-10-21 2014-08-14 Tanvex Biologics Corp. Separation of acetylated proteins from unacetylated proteins
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
BR112014025037A2 (pt) * 2012-04-09 2018-07-31 Daiichi Sankyo Company, Limited anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
US9321681B2 (en) * 2012-04-27 2016-04-26 United States Gypsum Company Dimensionally stable geopolymer compositions and method
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
MX352457B (es) * 2012-05-17 2017-11-24 Cyon Therapeutics Inc Metodos y usos para inhibidores de proproteina convertasa subtilisina kexina 9 (pcsk9).
ES2552371T3 (es) 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
JP2015530867A (ja) * 2012-06-15 2015-10-29 ジェネンテック， インコーポレイテッド 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法
TWI596115B (zh) * 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PT2929031T (pt) 2012-12-05 2018-01-19 Alnylam Pharmaceuticals Inc Composições de irna de pcsk9 e métodos de seu uso
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US10287317B2 (en) * 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
WO2014149699A1 (fr) 2013-03-15 2014-09-25 Eli Lilly And Company Protéine bifonctionnelle
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP2970501A2 (fr) * 2013-03-15 2016-01-20 Amgen, Inc. Protéines de liaison à un antigène humain se liant à la proprotéine convertase subtilisine kexine de type 9
EP2976117B1 (fr) 2013-03-22 2020-12-30 Amgen Inc. Injecteur et procédé d'assemblage
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
JP6417118B2 (ja) * 2013-05-31 2018-10-31 株式会社ビー・エム・エル Ｐｃｓｋ９測定用標準物質
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
EP2862877A1 (fr) 2013-10-18 2015-04-22 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
WO2014209384A1 (fr) 2013-06-28 2014-12-31 Amgen Inc. Procédés de traitement d'une hypercholestérolémie familiale homozygote
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
WO2015035215A1 (fr) 2013-09-05 2015-03-12 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
CA2920894C (fr) 2013-10-24 2023-03-14 Amgen Inc. Injecteur et procede d'assemblage
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
DE112014005747T5 (de) * 2013-12-17 2016-10-06 Kymab Limited Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
FR3014695A1 (fr) * 2013-12-17 2015-06-19 Kymab Ltd
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
GB2521356B (en) * 2013-12-17 2018-10-10 Kymab Ltd Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP2975058A1 (fr) * 2014-07-15 2016-01-20 Kymab Limited Anticorps pour leur utilisation dans le traitement de maladies liées à certains variants spécifiques de PCSK9 dans certaines populations spécifiques de patients
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
EP2886557A1 (fr) * 2013-12-17 2015-06-24 Kymab Limited Anticorps pour utilisation dans le traitement de maladies liées à certains variants spécifiques de PCSK9 dans certaines populations spécifiques de patients
WO2015092394A1 (fr) * 2013-12-17 2015-06-25 Kymab Limited Anticorps destinés à être utilisés pour traiter des états associés à des variants spécifiques de pcsk9 chez des populations de patients spécifiques
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
CN106460033B (zh) 2013-12-30 2021-12-24 阿特雷卡公司 使用核酸条形码分析与单细胞缔合的核酸
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
WO2015200438A1 (fr) * 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. Anticorps de haute affinité contre pcsk9
MX2017000527A (es) 2014-07-14 2017-08-10 Amgen Inc Formulaciones de anticuerpos cristalinos.
JP6783223B2 (ja) 2014-07-14 2020-11-11 アムジェン インコーポレイテッド 結晶性抗体製剤
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP4328245A3 (fr) 2014-07-15 2024-06-05 Kymab Ltd. Anticorps utilisés dans le traitement de pathologies associées à des variants pcsk9 spécifiques dans des populations de patients spécifiques
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
DE202015009007U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP2975059A1 (fr) * 2014-07-15 2016-01-20 Kymab Limited Anticorps pour utilisation dans le traitement de maladies liées à certains variants spécifiques de pcsk9 dans certaines populations spécifiques de patients
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
WO2016020799A1 (fr) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Méthodes pour réduire le cholestérol ldl
EP3193928A1 (fr) 2014-08-06 2017-07-26 Rinat Neuroscience Corp. Méthodes destinées à réduire le cholestérol ldl
WO2016023916A1 (fr) 2014-08-12 2016-02-18 Kymab Limited Traitement de maladie par la liaison d'un ligand à des cibles présentant un intérêt
MX2017003535A (es) 2014-09-16 2017-10-27 Regeneron Pharma Anticuerpos anti-glucagon y sus usos.
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2016071701A1 (fr) 2014-11-07 2016-05-12 Kymab Limited Traitement de maladie par liaison de ligand à des cibles d'intérêt
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
WO2016125495A1 (fr) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
CN105461809B (zh) * 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
TW201639891A (zh) * 2015-03-10 2016-11-16 索倫多醫療公司 結合ｐｓｍａ之抗體治療劑
MX384944B (es) * 2015-03-20 2025-03-14 Univ Aarhus Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".
AU2016248997B2 (en) * 2015-04-15 2019-03-07 ConcieValve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN105037554B (zh) * 2015-06-12 2019-04-12 成都贝爱特生物科技有限公司 抗人pcsk9抗体的制备及其用途
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
US20180363000A1 (en) * 2015-12-14 2018-12-20 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
WO2017110981A1 (fr) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
BR112018013256A2 (pt) * 2015-12-31 2018-12-11 Jiangsu Hengrui Medicine Co., Ltd. anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo
EP3401336A4 (fr) 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-pcsk9, fragment de liaison à l'antigène associé et application médicale associée
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
US10294299B2 (en) 2016-01-22 2019-05-21 MabQuest SA Immunological reagents
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2017163049A1 (fr) 2016-03-21 2017-09-28 Kymab Limited Anticorps anti-paludéens qui se lient à la protéine circumsporozoïte
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
CN107266575B (zh) * 2016-04-07 2021-12-24 天士力生物医药股份有限公司 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
EP3458988B1 (fr) 2016-05-16 2023-10-18 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
WO2018029474A2 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US11111313B2 (en) 2016-09-20 2021-09-07 WuXi Biologics Ireland Limited Anti-PCSK9 antibodies
CN107840893B (zh) * 2016-09-20 2022-02-25 信立泰(成都)生物技术有限公司 新型抗-pcsk9抗体
WO2018067987A1 (fr) 2016-10-06 2018-04-12 Amgen Inc. Formulations pharmaceutiques de protéines à viscosité réduite
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
CN108239150A (zh) * 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
EP4491234A3 (fr) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
US12023041B2 (en) 2017-03-21 2024-07-02 Teleflex Medical Incorporated Clip applier
CN119385632A (zh) 2017-03-21 2025-02-07 泰利福医疗公司 手术夹和施夹器
US20210148909A1 (en) * 2017-05-31 2021-05-20 North Carolina Central University Optimization of an active pcsk9 assay
CN107029243A (zh) * 2017-06-08 2017-08-11 厦门大学 一种多肽桥连的双酰腙连接键应用于醛衍生药物的递送
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019036181A1 (fr) 2017-08-18 2019-02-21 Amgen Inc. Injecteur sur-corps avec patch adhésif stérile
JP6913566B2 (ja) * 2017-08-23 2021-08-04 協同油脂株式会社 グリース組成物
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
EP3710589A4 (fr) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-c1s et procédés d'utilisation
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
WO2019152599A1 (fr) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Anticorps monoclonaux d'acide nucléique ciblant pcsk9 et procédés d'utilisation
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
CA3091764A1 (fr) * 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Domaines variables d'anticorps ciblant cd33, et leur utilisation
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体
CA3102032A1 (fr) 2018-06-05 2019-12-12 Anji Pharma (Us) Llc Compositions et methodes de traitement de la pancreatite
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
JP7247330B2 (ja) 2018-09-26 2023-03-28 テレフレックス メディカル インコーポレイテッド 安定化部材を備えたクリップアプライヤ
EP4640698A3 (fr) * 2018-11-16 2026-02-25 Memorial Sloan Kettering Cancer Center Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CN109776680B (zh) * 2019-01-25 2020-05-12 浙江蓝盾药业有限公司 抗人pcsk9单克隆抗体及其用途
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
CA3139943A1 (fr) 2019-05-17 2020-11-26 Regeneron Pharmaceuticals, Inc. Procedes bases sur le genome pour reduire le risque cardiovasculaire
WO2021050989A1 (fr) * 2019-09-13 2021-03-18 Duke University Anticorps zika et leur utilisation
WO2021058597A1 (fr) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de détermination du risque d'apparition de plaques artérielles chez un sujet
GB201913846D0 (en) 2019-09-25 2019-11-06 King S College London Biomarker
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
PH12022551299A1 (en) 2019-11-29 2023-11-20 Kymab Ltd Treatment for physiological iron overload
CA3164996A1 (fr) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anticorps anti-interleukine-23 p19 et leurs methodes d'utilisation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4146271A4 (fr) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et clec12a
WO2021247892A1 (fr) 2020-06-04 2021-12-09 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
MX2023011655A (es) 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
WO2022207785A1 (fr) 2021-03-31 2022-10-06 Kymab Limited Anticorps dirigés contre gfral
CA3219336A1 (fr) 2021-05-18 2022-11-24 Kymab Limited Utilisations d'anticorps anti-icos
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113480650B (zh) * 2021-06-30 2022-01-28 徐州医科大学 一种全人源靶向cd276的car-t细胞的制备方法及应用
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023076419A2 (fr) * 2021-10-27 2023-05-04 Twist Bioscience Corporation Anticorps de sars-cov-2 et méthodes d'utilisation
CN119161484A (zh) 2022-04-25 2024-12-20 武汉大学 抗asgr1单克隆抗体及其应用
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (fr) 2023-08-14 2025-02-20 Amgen Inc. Procédés de réduction de couleur jaune
CN121693519A (zh) * 2023-08-14 2026-03-17 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US896507A (en) 1908-04-06 1908-08-18 Theodore J Asch Sweat-band.
US1063008A (en) 1913-03-15 1913-05-27 William E Budd Vehicle-tire.
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022670A1 (fr) 1991-06-12 1992-12-23 Genpharm International, Inc. Detection precoce d'embryons transgeniques
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (fr) 1991-12-13 2003-03-12 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
EP0746609A4 (fr) 1991-12-17 1997-12-17 Genpharm Int Animaux transgeniques non humains capables de produire des anticorps heterologues
WO1994000569A1 (fr) 1992-06-18 1994-01-06 Genpharm International, Inc. Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP0773288A3 (fr) 1995-08-29 1997-07-09 Kirin Brewery Animal chimérique et méthode de production
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
AU4326197A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Pharmaceutical compositions
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US20070055056A1 (en) * 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US7968689B2 (en) 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US20070015696A1 (en) * 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
US20080103090A1 (en) * 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
US20060223090A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US20060223088A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US20070224663A1 (en) * 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20060246483A1 (en) * 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
FR2784749B1 (fr) 1998-10-14 2000-12-29 Instruments Sa Appareil de caracterisation optique de materiau en couche mince
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB2343233A (en) 1998-10-28 2000-05-03 Whitnash Plc Torsional vibration damper.
NL1011069C2 (nl) 1999-01-19 2000-07-20 Well Engineering Partners B V Werkwijze en installatie voor het inbrengen van een buis in een boorgat in de aardbodem.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1514933A1 (fr) * 1999-07-08 2005-03-16 Research Association for Biotechnology Protéine sécrétoire ou protéine de membrane
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030119038A1 (en) * 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US7029895B2 (en) * 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20100291099A1 (en) 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
JP2003512840A (ja) 1999-10-22 2003-04-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ラット脳に由来する核酸分子およびプログラム細胞死モデル
US20020081679A1 (en) 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
CA2399727A1 (fr) 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Nouveaux homologues de type subtilase (narc-1)
JP3753917B2 (ja) 2000-03-17 2006-03-08 茨木精機株式会社 包装体の整列搬出方法及びその装置
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
CA2436732A1 (fr) 2000-12-08 2002-06-13 Incyte Genomics, Inc. Molecules de modification et de maintenance proteiques
EP1414845A4 (fr) 2001-03-21 2009-07-08 Human Genome Sciences Proteines humaines secretees
US20070173473A1 (en) 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023243A1 (en) * 2001-06-13 2004-02-05 Yue Henry Proteases
CA2450793A1 (fr) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Anticorps bloquant l'activation d'un recepteur a activite proteine tyrosine kinase, procedes de criblage et utilisations associes
US20040038242A1 (en) * 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
EP1572903A2 (fr) 2002-02-11 2005-09-14 Alexion Pharmaceuticals, Inc. Agents therapeutiques immunologiques destines a la biodefense
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
ME00204B (me) 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1471152A1 (fr) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
MXPA05012571A (es) * 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
PT2409713E (pt) 2004-08-10 2015-10-09 Genzyme Corp Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
US20060147945A1 (en) * 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
CA2589860A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
US7682981B2 (en) * 2005-01-27 2010-03-23 Contour Semiconductor, Inc. Topography transfer method with aspect ratio scaling
WO2006124269A2 (fr) 2005-05-16 2006-11-23 Amgen Fremont Inc. Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles
EP1977763A4 (fr) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Préparation stabilisatrice contenant des anticorps
CA2637837A1 (fr) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Anticorps monoclonaux qui se lient a l'hemagglutinine de la sous-classe h5 du virus de la grippe aviaire et leurs utilisations
CA2900402C (fr) 2006-05-08 2018-01-16 Adaerata, Limited Partnership Polypeptide pcsk9, ligand associe audit polypeptide et necessaires et procedes utilisant ledit ligand
EP2194128B1 (fr) * 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Compositions et procédés d'inhibition d'expression du gène PCSK9
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008042383A1 (fr) 2006-10-02 2008-04-10 Armstrong World Industries, Inc. Procédé de préparation de polyesters de poids moléculaire élevé
US20100068194A1 (en) * 2006-10-24 2010-03-18 Dong-Ku Kim Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
CA2667989A1 (fr) * 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057458A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
EP2083861A4 (fr) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonistes de pcsk9
WO2008057457A2 (fr) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP5086618B2 (ja) * 2006-11-27 2012-11-28 オリンパス株式会社 カプセル型内視鏡
EP2453016A1 (fr) 2006-11-27 2012-05-16 Isis Pharmaceuticals, Inc. Procédés pour traiter l'hypercholestérolémie
EP2114451A2 (fr) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Préparations d'anticorps ant-il-13 et leurs utilisations
WO2008109871A2 (fr) 2007-03-08 2008-09-12 Irm Llc Structure cristalline de proprotéine convertase 9 (pcsk9) et utilisations de celle-ci
WO2008125623A2 (fr) * 2007-04-13 2008-10-23 Novartis Ag Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615114B1 (fr) 2007-08-23 2022-04-06 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
SG2013014352A (en) 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
WO2009134487A2 (fr) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Procédés optimisés d'administration d'arnds ciblant le gène pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
MX2010008688A (es) 2008-02-07 2010-08-30 Schering Corp Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
WO2009131740A2 (fr) 2008-04-23 2009-10-29 Amgen Inc. Variants neutralisants de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et ses applications
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
DE102008034203B4 (de) * 2008-07-21 2018-04-26 Airbus Helicopters Deutschland GmbH Herstellung von Faserverbundbauteilen mit Formkernen
ES2808660T3 (es) 2008-08-04 2021-03-01 Amgen Inc Proteínas de unión a antígeno para proproteína convertasa subtilisina kexina tipo 9 (PCSK9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010068526A1 (fr) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US8210622B2 (en) 2009-03-13 2012-07-03 Liberty Hardware Mfg. Corp. Adjustable product display assembly
WO2011028938A1 (fr) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
WO2011037791A1 (fr) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
EP2488544B1 (fr) 2009-10-15 2015-03-18 Monash University Ligands d'affinité et procédés de purification de protéine
WO2011053759A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes
WO2011053665A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
EP2493507A4 (fr) 2009-10-30 2013-11-20 Merck Sharp & Dohme Antagonistes et variants ax213 et ax132 pcsk9
EP2494355A4 (fr) 2009-10-30 2013-05-01 Merck Sharp & Dohme Dosage immunologique de pcsk9
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2545079A2 (fr) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation Anticorps présentant une liaison à l'antigène dépendante du ph
KR20130056871A (ko) * 2010-04-13 2013-05-30 브리스톨-마이어스 스큅 컴퍼니 Ｐｃｓｋ９에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
CN201712554U (zh) 2010-07-14 2011-01-19 李辉 电动汽车热管理系统
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2817015A1 (fr) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Complexes proteiques pour la liaison a un antigene, et leurs procedes d'utilisation
US8613308B2 (en) 2010-12-10 2013-12-24 Uop Llc Process for transferring heat or modifying a tube in a heat exchanger
CA2820953A1 (fr) 2010-12-22 2012-06-28 Genentech, Inc. Anticorps anti-pcsk9 et procedes d'utilisation
EP2481758A1 (fr) 2011-01-28 2012-08-01 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers (11566)
EP2650016A1 (fr) 2011-01-28 2013-10-16 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement basés sur des régimes de dosage particuliers (11565)
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
CN103562227B (zh) 2011-02-11 2016-12-21 诺瓦提斯公司 Pcsk9拮抗剂
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012170607A2 (fr) 2011-06-10 2012-12-13 Novartis Ag Utilisation d'antagonistes de pcsk9
WO2012168491A1 (fr) 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
RU2014101501A (ru) 2011-06-20 2015-07-27 Дженентек, Инк. Связывающие pcsk9 полипептиды и способы применения
CA2840482C (fr) 2011-07-14 2018-10-16 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
WO2013148284A1 (fr) 2012-03-29 2013-10-03 Genentech, Inc. Anticorps qui se lient à un site de clivage de pcsk9 et leurs procédés d'utilisation
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
JP2015530867A (ja) 2012-06-15 2015-10-29 ジェネンテック， インコーポレイテッド 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法
EP2703009A1 (fr) 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2706070A1 (fr) 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2970501A2 (fr) 2013-03-15 2016-01-20 Amgen, Inc. Protéines de liaison à un antigène humain se liant à la proprotéine convertase subtilisine kexine de type 9
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly
DE102023206495B3 (de) 2023-07-07 2024-11-21 Volkswagen Aktiengesellschaft Integrierter Schaltkreis, Anordnung sowie Verfahren zum Einkoppeln von optischen Signalen in einen integrierten Schaltkreis

Also Published As

Publication number Publication date
DK3666797T5 (da) 2024-08-26
NO2023012I1 (no) 2023-03-20
US8871914B2 (en) 2014-10-28
BR122018012430B8 (pt) 2021-07-27
KR101494932B1 (ko) 2015-02-26
IL252616A0 (en) 2017-07-31
TW201500374A (zh) 2015-01-01
LT3666797T (lt) 2023-08-10
FR16C0025I1 (fr) 2016-07-08
US20120093818A1 (en) 2012-04-19
ES2946083T3 (es) 2023-07-12
IL273353B1 (en) 2023-09-01
CY2016029I2 (el) 2017-04-26
IL204013A (en) 2017-07-31
US8889834B2 (en) 2014-11-18
TW200916481A (en) 2009-04-16
PE20140231A1 (es) 2014-03-08
EP2215124A1 (fr) 2010-08-11
HUE062493T2 (hu) 2023-11-28
US20130052201A1 (en) 2013-02-28
US20130085265A1 (en) 2013-04-04
JP5441905B2 (ja) 2014-03-12
DK2215124T3 (en) 2016-05-30
HUE028162T2 (en) 2016-12-28
HRP20230503T3 (hr) 2023-09-15
CN112415203A (zh) 2021-02-26
RS54756B2 (sr) 2024-07-31
US20090326202A1 (en) 2009-12-31
US20140228547A1 (en) 2014-08-14
TWI633122B (zh) 2018-08-21
FR16C0025I2 (fr) 2018-06-08
US20140357852A1 (en) 2014-12-04
CA2696252A1 (fr) 2009-02-26
JP2020058376A (ja) 2020-04-16
CN112390889A (zh) 2021-02-23
SI2215124T1 (sl) 2016-09-30
PH12013502285B1 (en) 2024-04-12
BR122018012430B1 (pt) 2019-10-08
MX2020008898A (es) 2020-10-12
CN104311666A (zh) 2015-01-28
US20130079502A1 (en) 2013-03-28
US20120213797A1 (en) 2012-08-23
EP2215124B2 (fr) 2023-07-19
US8981064B2 (en) 2015-03-17
US20140357850A1 (en) 2014-12-04
KR20260006647A (ko) 2026-01-13
US20140235831A1 (en) 2014-08-21
PE20140221A1 (es) 2014-02-21
BRPI0816117A2 (pt) 2015-03-10
PL2215124T3 (pl) 2016-08-31
JP2015166345A (ja) 2015-09-24
US9493576B2 (en) 2016-11-15
PE20180173A1 (es) 2018-01-22
IL204013B2 (en) 2025-07-01
PE20221507A1 (es) 2022-10-04
NO2016015I1 (no) 2016-08-12
HRP20160494T1 (hr) 2016-06-03
DK2215124T4 (da) 2024-01-29
US9045547B2 (en) 2015-06-02
PT3666797T (pt) 2023-06-07
AR068011A1 (es) 2009-10-28
IL252616B (en) 2020-05-31
CN104311667A (zh) 2015-01-28
RS54756B1 (sr) 2016-10-31
FI3666797T3 (fi) 2023-05-25
CL2008002495A1 (es) 2009-09-04
US20120020976A1 (en) 2012-01-26
EP2215124B1 (fr) 2016-02-24
US20140357851A1 (en) 2014-12-04
CO6230997A2 (es) 2010-12-20
CY2016023I1 (el) 2017-04-26
US20090142352A1 (en) 2009-06-04
US8030457B2 (en) 2011-10-04
US9056915B2 (en) 2015-06-16
ES2573258T3 (es) 2016-06-06
CY1117940T1 (el) 2017-04-26
US8859741B2 (en) 2014-10-14
TWI799416B (zh) 2023-04-21
HRP20160494T4 (hr) 2023-10-27
KR20240113594A (ko) 2024-07-22
US9920134B2 (en) 2018-03-20
LTC2215124I2 (lt) 2023-04-25
CN101932607B (zh) 2014-06-25
DE202008018562U1 (de) 2015-11-02
KR101702194B1 (ko) 2017-02-03
TN2010000063A1 (en) 2011-09-26
RS64295B1 (sr) 2023-07-31
US20140357853A1 (en) 2014-12-04
MY199051A (en) 2023-10-11
EP3666797B1 (fr) 2023-05-17
NZ584101A (en) 2012-09-28
IL273353A (en) 2020-05-31
PE20131400A1 (es) 2013-12-16
US8168762B2 (en) 2012-05-01
TWI441833B (zh) 2014-06-21
KR20230080496A (ko) 2023-06-07
JOP20080381B1 (ar) 2023-03-28
PL3666797T3 (pl) 2023-08-28
CY2016029I1 (el) 2017-04-26
US20120251544A1 (en) 2012-10-04
JP2023071833A (ja) 2023-05-23
KR20220031734A (ko) 2022-03-11
US8883983B2 (en) 2014-11-11
HK1143824A1 (zh) 2011-01-14
PL2215124T5 (pl) 2023-11-20
TW201500375A (zh) 2015-01-01
JP2018118974A (ja) 2018-08-02
PE20140220A1 (es) 2014-02-21
CN101932607A (zh) 2010-12-29
BRPI0816117B8 (pt) 2021-05-25
HUS1600029I1 (hu) 2016-09-28
EA032106B1 (ru) 2019-04-30
US20140357854A1 (en) 2014-12-04
ES2917423T3 (es) 2022-07-08
IL304868A (en) 2023-10-01
US20110027287A1 (en) 2011-02-03
AU2008288791B2 (en) 2014-10-30
WO2009026558A1 (fr) 2009-02-26
CA2696252C (fr) 2016-06-14
CN104311665A (zh) 2015-01-28
US8829165B2 (en) 2014-09-09
NL300818I2 (fr) 2016-07-14
US20130058944A1 (en) 2013-03-07
MY199053A (en) 2023-10-11
JP5705288B2 (ja) 2015-04-22
KR20180035947A (ko) 2018-04-06
JP2014043446A (ja) 2014-03-13
DK3666797T3 (da) 2023-05-30
PH12013502285A1 (en) 2016-08-08
MX375117B (es) 2025-03-06
AU2008288791A1 (en) 2009-02-26
US20140235830A1 (en) 2014-08-21
TWI675846B (zh) 2019-11-01
US8563698B2 (en) 2013-10-22
MY180102A (en) 2020-11-22
TW201500376A (zh) 2015-01-01
NO2016010I1 (no) 2016-06-03
EA201000356A1 (ru) 2010-08-30
EP3202791A1 (fr) 2017-08-09
IL317213A (en) 2025-01-01
MX2010001921A (es) 2010-03-11
LU93180I2 (fr) 2016-10-18
KR20210028741A (ko) 2021-03-12
EP2215124B9 (fr) 2023-12-27
US8871913B2 (en) 2014-10-28
JP2010536384A (ja) 2010-12-02
TWI890005B (zh) 2025-07-11
HUS1600036I1 (hu) 2016-10-28
UA127402C2 (uk) 2023-08-16
TW202330625A (zh) 2023-08-01
CN113402611A (zh) 2021-09-17
MA31978B1 (fr) 2011-01-03
BRPI0816117B1 (pt) 2018-12-18
US20130245235A1 (en) 2013-09-19
CR11328A (es) 2010-07-12
LTPA2016025I1 (lt) 2016-09-12
SI2215124T2 (sl) 2023-11-30
JP2016182114A (ja) 2016-10-20
TWI675848B (zh) 2019-11-01
JP5906333B2 (ja) 2016-04-20
TWI675847B (zh) 2019-11-01
TW201906871A (zh) 2019-02-16
US20120020975A1 (en) 2012-01-26
KR20170012592A (ko) 2017-02-02
FI2215124T4 (fi) 2023-10-10
LTPA2016021I1 (lt) 2016-06-27
KR20200074262A (ko) 2020-06-24
DE19207796T9 (de) 2023-02-23
TW201716444A (zh) 2017-05-16
KR20140064962A (ko) 2014-05-28
IL273353B2 (en) 2024-01-01
PE20091006A1 (es) 2009-08-14
JP6638009B2 (ja) 2020-01-29
ES2573258T5 (es) 2024-02-23
CN112409489A (zh) 2021-02-26
US20120027765A1 (en) 2012-02-02
US20150031870A1 (en) 2015-01-29
SG10201710183TA (en) 2018-01-30
US20150087819A1 (en) 2015-03-26
PE20140014A1 (es) 2014-01-31
DE19207796T1 (de) 2022-03-10
CY2016023I2 (el) 2017-04-26
SG184702A1 (en) 2012-10-30
US20140228545A1 (en) 2014-08-14
SI3666797T1 (sl) 2023-10-30
EP3666797A1 (fr) 2020-06-17
US20130079501A1 (en) 2013-03-28
US20140228557A1 (en) 2014-08-14
KR20100057070A (ko) 2010-05-28
PH12013502286A1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
NL301176I2 (nl) Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LUC00127I1 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2277509T3 (da) DPP IV inhibitorformuleringer
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
EP2120569A4 (fr) Dérivés spirochromanone
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK2294012T3 (da) Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
EP2045016A4 (fr) Broyeur
EP1992348A4 (fr) Combinaison pharmaceutique
EP2124556A4 (fr) Compositions pharmaceutiques
EP2291078A4 (fr) Dérivés d'oxazolobenzimidazole
NL300998I1 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
DK2035369T3 (da) Terapeutiske
EP2279532A4 (fr) Dérivés d'oxazolobenzimidazole